Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Recruiting 19Completed 7Not yet recruiting 3Active not recruiting 3Enrolling by invitation 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 660Carcinoma, Non-Small-Cell Lung 454Prostatic Neoplasms 384Neoplasms 376Lung Neoplasms 261Multiple Myeloma 246Colorectal Neoplasms 231Neoplasm Metastasis 214Melanoma 202Leukemia, Myeloid, Acute 165Ovarian Neoplasms 163Pancreatic Neoplasms 155Carcinoma, Renal Cell 141Squamous Cell Carcinoma of Head and Neck 137Lymphoma 134Brain Neoplasms 132Leukemia, Lymphocytic, Chronic, B-Cell 126Glioblastoma 126Recurrence 123Lymphoma, Non-Hodgkin 123Carcinoma, Hepatocellular 117Head and Neck Neoplasms 114Urinary Bladder Neoplasms 111Triple Negative Breast Neoplasms 107Stomach Neoplasms 106Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Uterine Cervical Neoplasms 100Hematologic Neoplasms 99Lymphoma, Follicular 95Sarcoma 93

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Infections × 1 year × Clear all
NCT05797246 2026-05-29

Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
21 enrolled

DNA Virus Infections, Infections, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Papilloma, Pathologic Processes, Recurrence, Respiratory Tract Diseases, Respiratory Tract Infections, Tumor Virus Infections, Virus Diseases, Neoplasms, Squamous Cell, Disease Attributes, Papillomavirus Infections

NCT06632912 2026-01-23

Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging

National Vaccine and Serum Institute, China

Phase 3 Active not recruiting
1,800 enrolled

Infections, Papillomavirus Infections

NCT05831111 2025-09-30

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

ModernaTX, Inc.

Phase 1 Active not recruiting
482 enrolled

Infections, Infectious Mononucleosis, Virus Diseases, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡